Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Heal

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Neuropharmacology|June 11, 2013
A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinilDavid J Heal, Niki W Buckley, Jane Gosden, et al.
Journal of Psychopharmacology (Oxford, England)|December 12, 2013
Differences in the neurochemical and behavioural profiles of lisdexamfetamine methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving ratsHelen L Rowley, Rajiv S Kulkarni, Jane Gosden, et al.
British Journal of Pharmacology|July 31, 2014
The behavioural response of mice lacking NK₁ receptors to guanfacine resembles its clinical profile in treatment of ADHDKatharine Pillidge, Ashley J Porter, Julia A Dudley, et al.
Journal of Psychopharmacology (Oxford, England)|April 6, 2017
Dopamine and μ-opioid receptor dysregulation in the brains of binge-eating female rats - possible relevance in the psychopathology and treatment of binge-eating disorderDavid J Heal, Michelle Hallam, Michael Prow, et al.
Neuropharmacology|June 14, 2024
Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuseFilomene G Morrison, Lori Jean Van Orden, Karla Zeitz, et al.
Drug and Alcohol Dependence|January 16, 2022
Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in ratsColleen Synan, Carrie Bowen, David J Heal, et al.
American Journal of Physiology. Endocrinology and Metabolism|December 15, 2011
Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channelsChristopher J Lynch, Qing Zhou, Show-Ling Shyng, et al.
Neuropharmacology|August 20, 2022
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act schedulingJack E Henningfield, Marion A Coe, Roland R Griffiths, et al.
Journal of Psychopharmacology (Oxford, England)|November 4, 2025
Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendationsJack E Henningfield, Sandra D Comer, Matthew L Banks, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Neuropharmacology|June 11, 2013
A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinilDavid J Heal, Niki W Buckley, Jane Gosden, et al.
Journal of Psychopharmacology (Oxford, England)|December 12, 2013
Differences in the neurochemical and behavioural profiles of lisdexamfetamine methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving ratsHelen L Rowley, Rajiv S Kulkarni, Jane Gosden, et al.
British Journal of Pharmacology|July 31, 2014
The behavioural response of mice lacking NK₁ receptors to guanfacine resembles its clinical profile in treatment of ADHDKatharine Pillidge, Ashley J Porter, Julia A Dudley, et al.
Journal of Psychopharmacology (Oxford, England)|April 6, 2017
Dopamine and μ-opioid receptor dysregulation in the brains of binge-eating female rats - possible relevance in the psychopathology and treatment of binge-eating disorderDavid J Heal, Michelle Hallam, Michael Prow, et al.
Neuropharmacology|June 14, 2024
Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuseFilomene G Morrison, Lori Jean Van Orden, Karla Zeitz, et al.
Drug and Alcohol Dependence|January 16, 2022
Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in ratsColleen Synan, Carrie Bowen, David J Heal, et al.
American Journal of Physiology. Endocrinology and Metabolism|December 15, 2011
Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channelsChristopher J Lynch, Qing Zhou, Show-Ling Shyng, et al.
Neuropharmacology|August 20, 2022
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act schedulingJack E Henningfield, Marion A Coe, Roland R Griffiths, et al.
Journal of Psychopharmacology (Oxford, England)|November 4, 2025
Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendationsJack E Henningfield, Sandra D Comer, Matthew L Banks, et al.
Pageof 5